Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Minny BhattyShumei KatoSarina A Piha-PaulAung NaingVivek SubbiahHelen J HuangDaniel D KarpApostolia M TsimberidouRalph G ZinnerWen-Jen HwuMilind M JavleSapna P PatelMimi I HuGauri R VaradhacharyAnthony P ConleyNishma M RamzanaliVeronica R HolleyRazelle KurzrockFunda Meric-BernstamYoung Kwang ChaeKevin B KimGerald S FalchookFilip JankuPublished in: Cancer (2018)
The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors.